CUSIP No. 00062936P1 Page 1 of 6 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
SCHEDULE 13G
Information Statement pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Final Amendment)
NPS Pharmaceuticals, Inc. (Name of Issuer)
Common Stock, $.001 par value
______________________________________________________________________
(Title of Class of Securities)
00062936P1
______________________________________________________________________
(CUSIP Number)
________________________
<PAGE>
CUSIP No. 00062936P1 Page 2 of 6 Pages
_________________________________________________________________
1) Name of Reporting Person Biotechnology
S.S. or I.R.S. Identification Investments
No. of Above Person Limited
_________________________________________________________________
2) Check the Appropriate Box (a) [ ]
if a Member of a Group (b) [ ]
_________________________________________________________________
3) SEC Use Only
_________________________________________________________________
4) Citizenship or Place Guernsey,
of Organization Channel Islands
_________________________________________________________________
Number of 5) Sole Voting 405,938 shares of Shares
Beneficially Power Common Stock, $.001
Owned by Each par value ("Common
Reporting Person Stock")
________________________________________
6) Shared Voting
Power -0-
________________________________________
7) Sole Disposi- 405,938 shares of
tive Power Common Stock
________________________________________
8) Shared Dis-
positive Power -0-
________________________________________
9) Aggregate Amount Beneficially 405,938 shares of
Owned by Each Reporting Person Common Stock
_________________________________________________________________
10) Check if the Aggregate
Amount in Row (9)
Excludes Certain Shares
_________________________________________________________________
11) Percent of Class
Represented by 3.4%
Amount in Row (9)
_________________________________________________________________
12) Type of Reporting
Person CO
<PAGE>
CUSIP No. 00062936P1 Page 3 of 6 Pages
Final Amendment to Schedule13G
______________________________
Reference is hereby made to the statement on Schedule 13G
originally filed with the Securities and Exchange Commission on February
14, 1995, as amended by Amendment No. 1 thereto filed on February 9, 1996.
Item 1(a) - Name of Issuer: NPS Pharmaceuticals, Inc.
Item 1(b) - Address of Issuer's Principal Executive Offices:
420 Chipeta Way
Salt Lake City, Utah 84108-1256
Item 2(a) - Name of Person Filing:
This statement is being filed on behalf of Biotechnology
Investments Limited ("BIL" or the "Reporting Person"). BIL
is a Guernsey, Channel Islands corporation.
Item 2(b) - Address of Principal Business Office:
P.O. Box 58
St. Julian's Court
St. Peter Port
Guernsey, Channel Islands GYI 3BP
Item 2(c) - Place of Organization:
Guernsey, Channel Islands
Item 2(d) - Title of Class of Securities:
Common Stock, $.001 par value ("Common Stock")
Item 2(e) - CUSIP Number: 00062936P1
Item 3 - Statements Filed Pursuant to Rules 13d-1(b) or 13d-2(b):
Not applicable.
Item 4 - Ownership.
(a) Amount Beneficially Owned:
405,938 shares of Common Stock
<PAGE>
CUSIP No. 00062936P1 Page 4 of 6 Pages
(b) Percent of Class:
3.4%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 405,938
shares
(ii) shared power to vote or to direct the vote: -0-
(iii) sole power to dispose or to direct the disposition
of: 405,938 shares
(iv) shared power to dispose or to direct the
disposition of: -0-
Item 5 - Ownership of Five Percent or Less of a Class:
This statement is being filed to report that as of
the date hereof the Reporting Person has ceased to be the
beneficial owner of more than five percent of the Common
Stock.
Item 6 - Ownership of More than Five Percent on Behalf of Another
Person:
Not applicable.
Item 7 - Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent
Company:
Not applicable.
Item 8 - Identification and Classification of Members of the Group:
Not applicable.
Item 9 - Notice of Dissolution of Group:
Not applicable.
Item 10 - Certification:
Not applicable.
<PAGE>
CUSIP No. 00062936P1 Page 5 of 6 Pages
Signature:
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
BIOTECHNOLOGY INVESTMENTS LIMITED
By: Old Court Limited
By /s/ Kathleen K. Schoemaker
_________________________________
Attorney-in-Fact
Date: February 12, 1997
<PAGE>
CUSIP No. 00062936P1 Page 6 of 6 Pages
OLD COURT LIMITED
P.O. Box 58, St. Julian's Court, St. Peter Port,
Guernsey, Channel Islands GYI 3BP
Our Ref: PF/domain/POA173
12 February 1997
Domain Associates
One Palmer Square
Princeton, New Jersey 08542
USA
Dear Sirs
Biotechnology Investments Limited
We, Old Court Limited hereby authorise you to execute on behalf of Old
Court Limited a Schedule 13G to be filed with the Securities and Exchange
Commission regarding Biotechnology Investments Limited's holdings of NPS
Pharmaceuticals, Inc.
Yours very truly
per pro Old Court Limited
/s/ S.H. Down /s/ S.E. Shaw
_________________________ _________________________
S.H. Down, Director S.E. Shaw, Director
We confirm that we have authorised Old Court Limited to grant the above
Power of Attorney.
Yours very truly
per pro Biotechnology Investments Limited
/s/ P.A.S. Firth
__________________________________
P.A.S. Firth, Authorised Signatory
